MaxCyte's Best In Class Technology Gray

Our Flow Electroporation® technology, specifically designed with primary cells in mind, maximizes cell recovery, minimizing loss of precious cells.

Maximize Cell Health and Recovery

20 mL Run

cell recovery

10 mL Run

5 mL Run

~96%

~93%

~92%

Average sample recovery: 90-95%+

Input

Output

MaxCyte’s robust technology eliminates platform-related variability, enabling consistent and reproducible outcomes across multiple donors and manufacturing sites.

TranspoCART cell production is reproducible across different facilities.

Demonstrated average 90% KO of CD38 across 8 different primary NK cell donors.

Reproducibility Across Donors and Sites

Learn more about this study

MaxCyte’s platform offers continuous scalability to accelerate optimization timelines, providing up to 4x the volume of competing electroporation platforms for clinical and commercial scale-up. This scalability can also significantly reduce allogeneic production costs, potentially lowering the Cost of Goods Sold (COGS) by up to $10,000 per patient dose

100 mL 50 mL 1 mL 400 µL 200 µL 50 µL 20 µL 0

OC-25x3TM

R-50x3/x8TM

OC-100TM

OC-400TM

G-/R-1000TM

CL-1.1TM

G-20KTM

CL-2TM

True Scalability

cell health & recovery

reproducibility

Scalability

100 mL 50 mL 1 mL 400 µL 200 µL 50 µL 20 µL 0